Evidence map›Paper›PMID 39841753›Full record

ArticlePLoS pathogens2025

Spatiotemporal profile of an optimal host response to virus infection in the primate central nervous system.

Olga A Maximova, Sarah L Anzick, Daniel E Sturdevant, Richard S Bennett, Lawrence J Faucette, Marisa St Claire, Stephen S Whitehead, Kishore Kanakabandi, Zong-Mei Sheng, Yongli Xiao and 4 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Olga A MaximovaLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.ORCID 0000-0002-8906-9738
Sarah L AnzickRocky Mountain Laboratories, Research Technologies Branch, Genomics Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Hamilton, Montana, United States of America.
Daniel E SturdevantRocky Mountain Laboratories, Research Technologies Branch, Genomics Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Hamilton, Montana, United States of America.
Richard S BennettLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.
Lawrence J FaucetteInfectious Disease Pathogenesis Section, Comparative Medicine Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.
Marisa St ClaireBioqual, Inc., Rockville, Maryland, United States of America.
Stephen S WhiteheadLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.
Kishore KanakabandiRocky Mountain Laboratories, Research Technologies Branch, Genomics Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Hamilton, Montana, United States of America.
Zong-Mei ShengLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.
Yongli XiaoLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.
John C KashLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.
Jeffery K TaubenbergerLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.
Craig MartensRocky Mountain Laboratories, Research Technologies Branch, Genomics Research Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Hamilton, Montana, United States of America.
Jeffrey I CohenLaboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, Maryland, United States of America.

Funding

National Institute of Allergy and Infectious Diseases INTRAMURAL
6 · The paper itself

Abstract

Viral infections of the central nervous system (CNS) are a major cause of morbidity largely due to lack of prevention and inadequate treatments. While mortality from viral CNS infections is significant, nearly two thirds of the patients survive. Thus, it is important to understand how the human CNS can successfully control virus infection and recover. Since it is not possible to study the human CNS throughout the course of viral infection at the cellular level, here we analyzed a non-lethal viral infection in the CNS of nonhuman primates (NHPs). We inoculated NHPs intracerebrally with a high dose of La Crosse virus (LACV), a bunyavirus that can infect neurons and cause encephalitis primarily in children, but with a very low (≤ 1%) mortality rate. To profile the CNS response to LACV infection, we used an integrative approach that was based on comprehensive analyses of (i) spatiotemporal dynamics of virus replication, (ii) identification of types of infected neurons, (iii) spatiotemporal transcriptomics, and (iv) morphological and functional changes in CNS intrinsic and extrinsic cells. We identified the location, timing, and functional repertoire of optimal transcriptional and translational regulation of the primate CNS in response to virus infection of neurons. These CNS responses involved a well-coordinated spatiotemporal interplay between astrocytes, lymphocytes, microglia, and CNS-border macrophages. Our findings suggest a multifaceted program governing an optimal CNS response to virus infection with specific events coordinated in space and time. This allowed the CNS to successfully control the infection by rapidly clearing the virus from infected neurons, mitigate damage to neurophysiology, activate and terminate immune responses in a timely manner, resolve inflammation, restore homeostasis, and initiate tissue repair. An increased understanding of these processes may provide new therapeutic opportunities to improve outcomes of viral CNS diseases in humans.

Indexed as

Central Nervous SystemEncephalitis, CaliforniaLa Crosse virusAnimalsMacaca mulattaNeuronsVirus Replication

Identifiers

PMID39841753
PMCPMC11753669

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.